MedTrace Logo

A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)

NCT05657873 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2026-05-07

No results posted yet for this study

Summary

The purpose of this study is to see whether adding liver stereotactic ablative radiotherapy/L-SABR to standard drug therapy is better than standard drug therapy alone for people with metastatic non-small cell lung cancer/NSCLC.

Conditions

  • Non Small Cell Lung Cancer
  • Non Small Cell Lung Cancer Metastatic
  • Non-small Cell Carcinoma
  • NSCLC
  • NSCLC Stage IV

Interventions

RADIATION

L-SABR

L-SABR will be delivered in a week during which the patient receives no chemotherapy. L-SABR can be on the same week or even day as anti-PD-(L)1 therapy.

BIOLOGICAL

Anti-PD-(L)1 based immunotherapy

Standard of care treatment (anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy

DRUG

Platinum based chemotherapy

Standard of care treatment (anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy

Sponsors & Collaborators

Principal Investigators

  • Paul Romesser, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-09
Primary Completion
2026-12-09
Completion
2026-12-09
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05657873 on ClinicalTrials.gov